Book Chapters, Letters, Serials

Book Chapters, Letters, Serials

1. Pollak M. Individualizing Interventions for Cancer Prevention. in Senn H-J, Morant R. (eds.) Recent Results in Cancer Research. 166: 63-70, 2005
2. Pollak M. Insulin-like growth factors and neoplasia. Novartis Found Symp. 262: 84-8, 98-107, 265-8, 2004
3. Narasimhadevera R, Pollak MN, Foulkes WD. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. (letter) J Natl Cancer Inst.95: 917-9, 2003
4. Pollak M. IGF-I, Insulin and Cancer Risk: Linking the Biology and the Epidemiology. In LeRoith D, Zumkeller W, Baxter R. (eds.) Insulin-Like Growth Factors (chapter 20) Eurekah.com., 2003
5. Pollak M. How do anti-oestrogens work? in Tobias J, Houghton J, and Henderson I. (eds.) Breast Cancer: New Horizons in Research and Treatment Oxford University Press, New York, 2001
6. Pollak M. Serum IGF-I, IGF-II,and IGFBP-3 Levels and Cancer Risk. Published on Web. www.dslabs.com/dslabs/1998_sabm.htm, 2000
7. Ma J, Stampfer M, Pollak M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF- binding protein-3. (letter) J Natl Cancer Inst. 92: 1949, 2000
8. Chan J, Stampfer M, Giovannucci E, Ma J, Pollak M. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Horm IGF Res 10 Suppl A: 32-3, 2000
9. Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res 10 Suppl A: 30-1, 2000
10. Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 10 Suppl A: 28-9, 2000
11. Byrne C, Hankinson S, Pollak M, Willett W, Colditz G, Speizer F. Insulin-like growth factors and mammographic density. Growth Horm IGF Res 10 Suppl A:24-5, 2000
12. Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 10 Suppl A: 6-7, 2000
13. Pollak M, Besser M, Cohen P, Rosenfeld R. Overview: First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia. Growth Horm IGF Research 10 Suppl A: 1-3, 2000
14. Pollak M. IGF-I, IGFBP-3 and Cancer Risk: An Update. (letter) Topical Endocrinology Suppl 7: 18-9, 2000
15. Pollak M. American Society for Clinical Oncology: Online continuing medical education segement. Published on Web. www.conference-cast.com/ASCO, 1999
16. Ma J, Giovannucci E, Pollak M, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. (letter) J Natl Cancer Inst. 91: 2051-2, 1999
17. Pollak M. Cancer controversy. Nature 392: 752, 1998
18. Pollak M, Ingle J, Suman V, Kugler J. Rationale for combined antiestrogen-somatostatin analogue therapy of breast cancer. in Salmon S.(ed) Adjuvant Therapy of Cancer VIII Lipincott, Philadelphia, 145-52, 1997
19. Pollak M, The potential role of somatostatin analogues in the management of breast cancer. Peptide Therapy Reviews 8: 1-13, 1996
20. Pollak M. Hormonal therapies for breast cancer. Current Oncology 3: s46-s52, 1996
21. Pollak M. Enhancement of the antineoplastic effects of tamoxifen by somatostatin analogues. in Kellen J. (ed) Tamoxifen: Beyond the Antiestrogen, Birkhauser, Boston, 359-68, 1996
22. Pollak M. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. (letter) J Natl Cancer Inst. 87: 608-9, 1995
23. Pollak M. Mutagen sensitivity as as risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. (letter) J Natl Cancer Inst. 87: 458, 1995
24. Pollak M. Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. (letter) J Natl Cancer Inst. 87: 1557-8, 1995
25. Arbour L, Narod S, Glendon G, Pollak M, Seymour R, Miner L, Leung P. In vitro fertilization and family history of breast cancer. (letter) Lancet. 344: 610-1, 1994
26. Pollak M. Effects of adjuvant tamofixen therapy on growth hormone and IGF-1 physiology. in Salmon S. (ed.) Adjuvant Therapy of Cancer VII. Lipincott, Philadelphia, 43-55, 1993
27. Pollak M. Reference for patients: valuable or misguided? (book review of: Everyone's Guide to Cancer Therapy, Dollinger M.) J Can Med Assoc. 147: 213-4, 1992
28. Pollak M. Timing of surgery in breast cancer. (letter) Lancet. 337: 1603-4, 1991
29. Pollak M. Therapeutic Implication of Recent Growth Factor Research. in High Risk Cancer Breast Cancer, Ragaz J (ed), Springer Verlag, New York, 1991
30. Pollak M. Review Bias. (letter) New England Journal of Medicine. 322: 638, 1989
31. Pollak M. Recombinant GM-CSF in myelosuppression of chemotherapy. (letter) New England Journal of Medicine. 320: 253-4, 1989
32. Pollak M. Epidermal growth factor receptors and breast cancer. (letter) Lancet. 2: 562, 1987